猫咪AV成人 Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer 2 March 2026 | Press release
猫咪AV成人 Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Pol胃) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer 23 February 2026 | Press release
猫咪AV成人 Strengthens Leadership Team to Accelerate Late-Stage Development of Potential First-in-Class Oncology Pipeline 16 February 2026 | Press release
猫咪AV成人 to Present at the 44th Annual J.P. Morgan Healthcare Conference 7 January 2026 | Press release
猫咪AV成人 Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need 17 November 2025 | Press release
猫咪AV成人 Announces Phase 1/2a Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO Congress 2025 17 October 2025 | Press release
猫咪AV成人 to Announce First Phase 1/2a Data for DNA Polymerase Theta (Pol胃) Inhibitor ART6043 in Advanced Solid Tumors in Oral Presentation at ESMO 13 October 2025 | Press release
猫咪AV成人 Receives U.S. FDA Fast Track Designation for alnodesertib in ATM-negative Metastatic Colorectal Cancer (mCRC) 24 September 2025 | Press release
猫咪AV成人 Appoints Michael T. Andriole as CEO and Director to Advance Alnodesertib (ART0380) into Late-stage Development 12 August 2025 | Press release
猫咪AV成人 Reports Differentiated Clinical Activity in STELLA Phase 1/2a Study for Lead Program ART0380 at the American Association for Cancer Research (AACR) Annual Meeting 2025 29 April 2025 | Press release